No ocular manifestations associated with inflammatory bowel disease, study finds
August 14, 2022
In a study, investigators found that no characteristics of inflammatory bowel disease are related to ocular manifestations of the disease.
© 2022 MJH Life Sciences™ and Opthalmology Times Europe. All rights reserved.
All Articles
Applying cryopreserved amniotic membrane following intravitreal injection
August 15, 2022
CAM encourages corneal healing in patients with ocular surface disease.
Phase 3 study of CPN-302: Positive topline results for post-cataract surgery drug candidate
August 13, 2022
The companies note that data from Study CPN-302 confirm the results in the first Phase 3 study, CPN-301, and they demonstrate the clear benefits of treating patients after cataract surgery with APP13007.
Weekly review in ophthalmology: 6-12 August
August 12, 2022
An end-of-week review of what happened in ophthalmology from 6 to 12 August 2022.
A window into the world of academic retina practice today
August 11, 2022
Dr Jayanth Sridhar shares a day in the life of an academic retina specialist.
Intravenous bevacizumab repackaged for intravitreal use: Making the sight-saving treatment safer
August 10, 2022
Although off-label repackaged bevacizumab syringes appear to satisfy an urgent clinical and financial need for patients with a variety of retinal disorders, they are known to be associated with considerable public health concerns due to the risks posed to patients from compounding pharmacies’ lack of compliance with a variety of FDA requirements.
The need for precision management in glaucoma moves field forward
August 08, 2022
Genotyping and artificial intelligence are together starting to predict the progression of glaucoma in individual patients, sparing them from suboptimal treatments and side effects. Recent research efforts are exploring modifiable risk factors such as caffeine consumption.
High-tech, noninvasive imaging identifies early glaucoma
August 06, 2022
Flavoprotein fluorescence could serve as a new biomarker, according to a Mount Sinai study. This measurement could potentially be used as a first-line indicator to monitor of glaucoma progression for the patient and the physician.
First-ever retinal gene therapy: Does real-world experience back its use?
August 04, 2022
Recent reports of retinal atrophy have raised concerns on potential long-term safety.